Drugs Information Center(DIC)

WARNINGS AND PRECAUTIONS- Cardiac Failure Myocardial Ischemia Myocardial Ischemic Events in Large Long-Term Prospective Randomized Controlled Trials Congestive Heart Failure and Myocardial Ischemia During Coadministration With Insulin Weight Gain Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive heart failure in some patients. After initiation of Thiazolidinediones, and after dose increases, observe patients carefully for signs and symptoms of heart failure (including excessive, rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop, the heart failure should be managed according to current standards of care. Furthermore, discontinuation or dose reduction must be considered. Limitations of Use: It should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Coadministration with insulin is not recommended. Use with nitrates is not recommended. DOSAGE AND ADMINISTRATION Start at 4 mg daily i

WARNINGS AND PRECAUTIONS- Avoid use in pregnancy. Fetal/Neonatal Morbidity and Mortality - can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Drugs that act on the renin angiotensin system can cause fetal and neonatal morbidity and mortality when used in pregnancy. In several dozen published cases, ACE inhibitor use during the second and third trimesters of pregnancy was associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Hypotension- Volume depletion should be corrected prior to administration . Impaired Renal Function - Hypertension Subscribe to Drugs Information Center by Email